Aanastra
Aanastra discloses PEP-CAR, an anti-CD19 in vivo CAR-T strategy combining engineered RNA and targeting peptides for cancer and autoimmune disease. The public website does not establish a registered clinical program or validated patient outcomes.
Corporate information
- Company entity
- Aanastra
- Headquarters / principal office
- Pacific Palisades, California, USA; Nimes, FranceOffice location disclosed on the corporate website; a sole legal or global headquarters is not inferred. ↗
- Founded
- Not verified
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://aanastra.com/ ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Aanastra discloses PEP-CAR, an anti-CD19 in vivo CAR-T strategy combining engineered RNA and targeting peptides for cancer and autoimmune disease. The public website does not establish a registered clinical program or validated patient outcomes.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.